- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05606796
Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Ethical approval has been obtained from the Health Research Ethics Committee of Lagos University Teaching Hospital.
Patients will be recruited from the weekly glaucoma clinic, Monday, Thursday, and Friday general clinics. Each participant would be seen for a period of 12 weeks; at baseline visit, and weeks 4, 8 and 12, in which topical, label-masked preserved or preservative free latanoprost would be dispensed, with patient instructed to instill one drop of 0.005% latanoprost by 9:00pm (± 1 hour). Efficacy of the two eye drops will be assessed by measuring the intraocular pressure 3 times a day at every visit. Safety and potential adverse effects of the drops will be evaluated in terms of ocular symptoms and tear parameters. Ocular symptom values of the patients will be evaluated.
All patients will undergo ocular examinations, including visual acuity assessment, slit lamp biomicroscopy, intraocular pressure, tear film breakup time (TBUT), fluorescein staining, schirmer test, gonioscopy, standard automated perimetry, and ophthalmoscopy. Tolerability will be evaluated with the frequency and percentage of distributions of severity level using the OSDI questionnaire in each group after administration at weeks 4 and 12, respectively. The symptoms checked during follow-up visits will include; pruritus, burning/stinging, blurred vision, tearing, sticky eye sensation, eye dryness sensation, and foreign body sensation. Quality of life would be evaluated at baseline visit and at week 12, using the standard quality of life Q-15 questionnaire.
A research team would be involved in carrying out this research, Comprising the principal researcher, a pharmacist, and 2 ophthalmic nurses. Results will be collated and analysed by the principal researcher. The entire research would be carried out over a period of 9 months, from December 2022 to August 2023.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Uzoma C Joan, MBBS
- Phone Number: +2348033336844
- Email: chinyuzoma@gmail.com
Study Locations
-
-
Lagos State
-
Lagos, Lagos State, Nigeria, PMB 12003
- Recruiting
- Guinness Eye Centre. Lagos University Teaching Hospital.
-
Contact:
- ADEOLA ONAKOYA, FICO, MBBS,
- Phone Number: +234807090401
- Email: adeolaonakoya@outlook.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Recently diagnosed, consenting high tension, primary open angle glaucoma or ocular hypertensive patients.
- Forty years and above.
- Intraocular pressure of 21- 30mmHg (millimetres of mercury)
- Willingness to participate in the study.
Exclusion Criteria:
- Patients under 40 years of age.
- Diabetic patients
- Patients on other anti- glaucoma medications.
- Patients on topical immunosuppressive medication.
- Patients on anti-depressants.
- Patients who have had any form of ocular surgery or intervention such as cryotherapy.
- Patients using contact lens.
- Patients on any form of topical medication in the last 1 month.
- Patients diagnosed or suspected to have Sjogren syndrome.
- Patients being managed for Steven-Johnson's syndrome, ocular cicatricial pemphigoid.
- Pregnant patients.
- Previous glaucoma surgery and any refractive surgery <12 month prior to enrolment.
- Only eye patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Preserved latanoprost
Benzalkonium chloride (BAK) preserved latanoprost 0.005%. 1 drop will be instilled into the conjunctival sac of both eyes of patient, at about 9pm daily, to reduce intraocular pressure. |
1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
|
Experimental: Preservative-free latanoprost
Preservative-free (Benzalkonium chloride-free) latanoprost 0.005%. 1 drop will be instilled into the conjunctival sac of both eyes of patient, at about 9pm daily, to reduce intraocular pressure. |
1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraocular pressure assessment.
Time Frame: 12 weeks
|
Intraocular pressure measured in millimetre mercury (mmHg), will be assessed every 4 weeks at 8am,12pm and 4pm.
Normal intraocular pressure ranges between 9 to 21mmHg.
Any intraocular pressure values above 21mmHg would be considered abnormal.
Pressures below 6mmHg will be considered as hypotony.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ocular surface disease index (OSDI) questionnaire.
Time Frame: 4 weekly in 12 weeks.
|
The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers.
Patient's responses are rated on a scale of 0 to 4, with 0 corresponding to "none of the time" and 4 corresponding to "all of the time."
A final score is calculated, which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.
|
4 weekly in 12 weeks.
|
Quality of life-15 questionnaire.
Time Frame: Baseline visit and week 12.
|
Questionnaire is composed of 15 items, 4 domains which address factors of visual disability: central and near vision, peripheral vision, dark adaptation and glare, and outdoor mobility.
Poorer QoL scores are associated with worse functional status and increased visual morbidity from glaucoma
|
Baseline visit and week 12.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: ADEOLA ONAKOYA, MBBS, FMCOph, FICO, Lagos State University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Chinyei
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Effect of Drug
-
General Hospital of Ningxia Medical UniversityNot yet recruitingEffect of Drug | Adverse Effect of OpioidsChina
-
Walter Reed National Military Medical CenterUnited States Department of Defense; General Services Administration (GSA)Active, not recruitingAdverse Drug Effect of Opioids | Adverse Drug Effect of BenzodiazepinesUnited States
-
Penn State UniversityEnrolling by invitationEffect of DrugUnited States
-
Dow University of Health SciencesCompleted
-
Assam Medical CollegeCompleted
-
Hematology Oncology Associates of Central New YorkNot yet recruitingEffect of Drug
-
Auburn UniversityVDF FutureCeuticals Inc.Completed
-
Sichuan Provincial People's HospitalCompleted
-
Dow University of Health SciencesCompletedEffect of DrugPakistan
-
Tongji HospitalRecruitingEffect of DrugChina
Clinical Trials on Latanoprost 0.005% Ophthalmic Solution
-
TearClear CorpActive, not recruitingElevated Intraocular PressureUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open-angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open-angle GlaucomaUnited States
-
Santen Pharmaceutical Co., Ltd.CompletedPrimary Open Angle Glaucoma or Ocular HypertensionJapan
-
Santen Pharmaceutical Co., Ltd.CompletedPrimary Open Angle Glaucoma, Ocular HypertensionJapan
-
Santen Pharmaceutical Co., Ltd.CompletedPrimary Open Angle Glaucoma | Ocular HypertensionJapan
-
JeniVision, Inc.Active, not recruitingOcular Hypertension | Open Angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open Angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open Angle GlaucomaUnited States
-
Alcon ResearchCompletedOcular Hypertension | Open-angle Glaucoma